Breaking News

The partners will commercialize Counsyl's Expanded Carrier Screening Test as preconGen, beginning in Spain, Italy, Portugal, Switzerland, and Colombia.

The revenue increase was driven by a 41 percent rise in product sales.

The company reported $4.77 billion in first quarter revenues, driven by growth in all of its business segments.

The company has agreed to a takeover bid that values it at roughly €171 million ($186.3 million).

The firm guided second quarter revenues to between $62 million and $64 million and revised its full-year 2017 revenue guidance to between $255 million and $265 million.

BD said that it is also working with additional partners to license the indexing technology, which quantifies target molecules in complex biological samples.

The company said that it received orders for 135 of its NovaSeq sequencing instrument in the first quarter 2017.

The researchers analyzed samples from 161 dog breeds to examine the origins of modern dogs and examine the haplotypes of each clade.

Respondents to a 2013 survey described changes in the way hereditary breast and ovarian cancer risk is assessed, interpreted, and conveyed to patients following the court decision.

Gyros will distribute certain of Luxembourg Bio Technologies' coupling agents for peptide synthesis.

Oxford Nanopore filed two lawsuits, one in the UK and one in Germany.

 The researchers noted that heritability of PTSD differed by sex, and that it overlapped with schizophrenia and other mental disorders. 

The firm will scale up manufacturing of its nanopore sensor, expand its executive team, and push development of its sequencing and genome mapping applications.

Driven by strong demand from the company's pharma customers, it posted sales of $498 million, beating the average Wall Street estimate of $488.6 million.

The financing, which comes on the heels of a $30 million Series C round, will be used for operating capital.

The company's diagnostics business saw 8 percent growth, while its Covance segment retreated 2 percent. The firm lowered its adjusted EPS estimate for the full year. 

Influenza revenues rose 112 percent due to an especially long and severe respiratory disease season, dominated by a virulent H3N2 strain of influenza.

The firm has received approval for two unspecified clinical tests, with a permit under the molecular genetic testing category.

The researchers traced the expression of related genes to neural tissues and noted a link between puberty timing and cancer risk.

The deal gives Tanon rights to sell Sygnis's InstantBlue stain and Ultrafast blotting buffer in China and expands on a previous deal covering precast gels.

Using point mutation and structural variant patterns in 133 ovarian cancer cases, researchers identified seven clusters to classify the disease and predict patient outcomes.

The partners will work together to develop a breast cancer recurrence risk score using the company's technology.

Diaceutics will use the data to help its pharmaceutical industry clients speed their rollouts of new cancer drugs.

Analyses of Clostridium difficile isolates from hundreds of European hospitals led to clusters of apparent hospital-acquired cases and of infections with other potential sources.

The company said revenues for the quarter and full-year 2016 included sales of Olerup HLA typing products, which CareDx got through its acquisition of Allenex.

Pages

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.